Paper Details

  1. Home
  2. Paper Details

A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound Paclitaxel for advanced solid malignancies.

Author: ChenLee-may, ChienAmy J, DubeySarita, FongLawrence, HuangYong, HyltonNola M, IlliJulie A, JahanThierry M, Kashani-SabetMohammed, KoAndrew H, KochKevin M, KornWolfgang M, MoasserMark M, RosenbergJonathan E, RyanCharles J, SmallEric J, YehBenjamin M

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Chemotherapy often struggles to reach all cancer cells, limiting its effectiveness. This study investigates a new approach: using high doses of tyrosine kinase inhibitors (TKIs) to temporarily improve blood flow to tumors, allowing chemotherapy drugs to reach more cancer cells.
Paper Details　
Original Abstract of the Article :
Systemic chemotherapy fails to access much of the tumor burden in patients with advanced cancer, significantly limiting its efficacy. In preclinical studies, brief high doses of tyrosine kinase inhibitors (TKI) targeting the human epidermal growth factor receptor (HER) family can prime tumor vascula...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/19706807

データ提供：米国国立医学図書館（NLM）

A New Approach to Conquer Advanced Cancer: Chemosensitization

The fight against advanced cancer is like battling a fierce sandstorm, where conventional chemotherapy often fails to reach the full extent of the tumor. This study investigates a novel approach, called chemosensitization, aimed at improving the efficacy of chemotherapy in patients with advanced solid malignancies. It focuses on using brief, high doses of tyrosine kinase inhibitors (TKIs) targeting the HER family of receptors to prime tumor vasculature for optimal chemotherapeutic delivery. This approach, much like clearing a path through a sandstorm, aims to enhance the effectiveness of chemotherapy by increasing its access to the tumor.

A Phase I Trial: Exploring the Clinical Relevance of Chemosensitization

The study delves into the clinical relevance of this chemosensitization approach through a Phase I trial. The results, like the shifting sands, offer valuable insights into the safety and feasibility of this novel strategy. By employing a two-day lapatinib pulse preceding nanoparticle albumin-bound paclitaxel, researchers explore the potential of chemosensitization to enhance the efficacy of chemotherapy in treating advanced cancers.

A Glimpse into a Promising Future

This study represents a significant step towards optimizing chemotherapy for patients with advanced cancer. It offers a beacon of hope, much like a desert oasis, promising a more effective and targeted approach to combating this formidable disease.

Dr.Camel's Conclusion

This Phase I study offers a glimmer of hope in the fight against advanced cancer. It demonstrates the potential of chemosensitization, a novel approach that could significantly improve the effectiveness of chemotherapy. This research is a reminder that even in the vast and challenging landscape of cancer treatment, innovation and scientific exploration can lead to breakthroughs that offer new hope for patients.

Date :
  1. Date Completed 2009-12-11
  2. Date Revised 2021-10-20
Further Info :

Pubmed ID

19706807

DOI: Digital Object Identifier

NIHMS263170

Related Literature

Article Analysis
・Effects of paclitaxel (with albumin) injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.